key: cord-0955733-llzxgqx6
authors: Krasniqi, Besir; Stevaert, Annelies; Van Loy, Benjamin; Nguyen, Tien; Thomas, Joice; Vandeput, Julie; Jochmans, Dirk; Thiel, Volker; Dijkman, Ronald; Dehaen, Wim; Voet, Arnout; Naesens, Lieve
title: Betulonic acid derivatives inhibiting coronavirus replication in cell culture via the nsp15 endoribonuclease
date: 2020-12-10
journal: bioRxiv
DOI: 10.1101/2020.12.10.418996
sha: e1bde25b1d68ba97f07ae1025d1028f6efd75b6c
doc_id: 955733
cord_uid: llzxgqx6

The lack of medication to suppress coronavirus infections is a main reason for the dramatic course of the COVID-19 pandemic. There is an urgent need to identify suitable coronavirus drug targets and corresponding lead molecules. Here we describe the discovery of a class of coronavirus inhibitors acting on nsp15, a hexameric protein component of the viral replication-transcription complexes, endowed with immune evasion-associated endoribonuclease activity. SAR exploration of these 1,2,3-triazolo fused betulonic acid derivatives yielded lead molecule 5h as a strong inhibitor (antiviral EC50: 0.6 μM) of human coronavirus 229E replication. An nsp15 endoribonuclease active site mutant virus was markedly less sensitive to 5h, and selected resistance to the compound mapped to mutations in the N-terminal part of nsp15, at an interface between two nsp15 monomers. The biological findings were substantiated by the nsp15 binding mode for 5h, predicted by docking. Hence, besides delivering a distinct class of inhibitors, our study revealed a druggable pocket in the nsp15 hexamer with relevance for anti-coronavirus drug development.

The current SARS-CoV-2 pandemic is causing a major crisis in terms of human health and socioeconomic losses. Within a period of ~20 years, SARS-CoV-2 is the third zoonotic coronavirus (CoV) to enter the human species, coming after SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome). 1 Besides, four human CoVs (i.e. HCoV-229E, -HKU1, -NL63, and -OC43) are endemic in the population and account each year for 15 to 30% of common colds. 2 These can evolve into life-threatening lower respiratory tract infections in elderly, children and persons at risk. 3, 4 Finally, the Coronaviridae family contains several species causing serious disease in pets and livestock. 5 Most young persons infected with SARS-CoV-2 experience no or only mild symptoms of respiratory illness. 6 In contrast, in persons with comorbidities or higher age, the viral replication phase is typically followed by a second phase that is characterized by hyperinflammation, acute respiratory distress syndrome and multi-organ failure. 7 Hence, management of COVID-19 most likely requires antiviral drugs to suppress initial virus replication, plus anti-inflammatory medication, like corticosteroids, to treat severe cases. 8 Several CoV proteins may be suitable drug targets, 9, 10 but, at the moment, only two drug classes are far advanced in clinical testing, i.e. antispike antibodies 11 and the nucleotide analogue remdesivir, which inhibits the CoV polymerase. The concept to inhibit nsp15 is thus unique, since it combines a direct antiviral effect with the potential to revert viral evasion from host cell immunity.

We here report identification of a class of coronavirus nsp15 inhibitors with 1,2,3-triazolo fused betulonic acid structure. We describe their synthesis, structure-activity relationship and the mechanistic findings, in particular resistance data, that corroborate nsp15 as their antiviral target.

These biological data accord with the binding model that we obtained by compound docking in the hexameric nsp15 protein structure. The model also explains why the current lead is active against human coronavirus 229E, but not other coronaviruses like SARS-CoV-2. In short, our study validates the nsp15 protein, and particularly the interface where the lead compound binds, as a druggable and pertinent target for developing CoV inhibitors.

The 1,2,3-triazolo fused betulonic acid derivatives (Scheme 1) were designed and synthesized in the context of a pharmacological hit discovery program. Betulonic acid bears a pentacyclic triterpenoid core, present in a wide variety of agents with potential pharmacological use, [26] [27] [28] like the HIV maturation inhibitor bevirimat. 29, 30 We decided to fuse betulonic acid with a 1,2,3-triazole moiety, which has the unique property to both accept and donate hydrogen bonds. [31] [32] [33] [34] These derivatives were synthesized by our recently developed and convenient "triazolization" method to prepare 1,2,3-triazoles from primary amines and ketones. [35] [36] [37] [38] First, Jones oxidation was performed to convert betulin 1 into betulonic acid 2 (Scheme 1). 39 Betulin 1, a natural compound isolated from the bark of Betula species, is commercially available. [40] [41] [42] Next, the triazolization method was applied to betulonic acid 2 as the ketone source, using primary amines 3 and 4nitrophenyl azide 4, and the previously reported reaction conditions. 13 This yielded a series of sixteen 1,2,3-triazolo fused betulonic acids 5, most of which were isolated at high yield (~80%; Table 1 ). Diverse primary amines 3 were attached to the 1,2,3-triazole ring to introduce a variety of aromatic or aliphatic moieties. We next evaluated the compounds in cell-based assays with diverse DNA-and RNA-viruses, and observed strong activity in human embryonic lung (HEL) fibroblast cells infected with HCoV-229E.

We used a viral cytopathic effect (CPE) reduction assay, in which protection against CPE (expressed as the antiviral EC50 value) was monitored by the MTS cell viability assay and verified by microscopy. The MTS assay was also used to quantify compound cytotoxicity (expressed as the CC50 value) in mock-infected cells. Whereas the starting compounds betulin 1 and betulonic acid 2 were virtually inactive, all 1,2,3-triazolo fused betulonic acid derivatives proved to be highly effective CoV inhibitors ( Table 1) . The one exception was 5i (EC50 value: 13 µM), which bears a non-aromatic cyclohexanemethyl substituent. Apparently, introducing this bulky group caused a considerable reduction in antiviral activity and selectivity. Several compounds in the series had EC50 values below 1 µM, which makes them superior to two known CoV inhibitors which we used as reference compounds, i.e. K22 43 and GS-441524, the nucleoside form of remdesivir. 14 Three analogues stood out for having superior selectivity, i.e. 5n, 5g and 5h, having a selectivity index (ratio of CC50 to EC50) of 27, 31 and 76, respectively. The capacity of 5h to fully suppress HCoV-229E replication at non-toxic concentrations is evident from the microscopic images in Fig. 1A and the dose-response curves in Fig. 1B . Also, 5h fully prevented the formation of dsRNA intermediates of CoV RNA synthesis, as demonstrated by immunofluorescence staining of dsRNA in HCoV-229E-infected human bronchial epithelial 16HBE cells (Fig. 1C) . To conduct a SAR exploration around lead compound 5h (Scheme 2 and Table 2 ), we first investigated the contribution of the α-methyl-phenylene moiety. Compound 5q, in which this entire moiety is missing, had ~6-fold lower antiviral activity than 5h. When only the α-methyl was missing (5r), the activity was not affected. Compound 5s, which is the epimer at the 1,2,3-triazole substituent, displayed almost the same EC50 value as 5h, indicating that isomerism does not alter the activity. Cytotoxicity was however slightly decreased, resulting in an even better selectivity index (≥ 90) than that of 5h. In order to elucidate the role of the isopropenyl side chain, we reduced 10 this moiety by hydrogenation, yielding compound 5t which was 10-to 20-fold less active.

Replacement of the carboxylic acid by a methyl group (5u) proved deleterious.

Scheme 2. SAR study around compound 5h.

a Isolated yield after column chromatography. 

Given the robust activity of the betulonic acid derivatives against HCoV-229E, we used this virus to reveal their mechanism of action and appreciate how their anti-CoV activity spectrum may be for multiple comparisons using Holm-Sidak (α = 0.05). *, P < 0.05; **, P < 0.01; ***, P < 0.001.

To predict the possible binding site of 5h, the compound was docked into the X-ray structure of hexameric nsp15 protein from HCoV-229E (PDB code: 4RS4). This hexameric structure formed by two trimers is the functional form of nsp15. 15 First, a few substitutions (see Experimental section for all details) were introduced to render the protein sequence identical to that of the HCoV-229E

virus used in the biological assays. By using a pocket-detection protocol implemented on the Site Analysis of the nsp15 sequence similarity between HCoV-229E and SARS-CoV-2 showed that a few residues in the pocket are not conserved. This explains why docking 5h into the SARS-CoV-2 nsp15 hexamer was unable to identify a similar pose within the top solutions. The largest influence seems attributed to the residue at position 244/245, since substituting Thr245 (present in HCoV-229E) by Gln244 (the corresponding residue in SARS-CoV-2) abrogates a hydrogenbond interaction with the 1,2,3-triazole group of 5h (Fig. 5) . Additionally, the loop between Val/Ile63 and Leu/Pro65 has a slightly different orientation in these two CoV nsp15 proteins. Both factors may explain why 5h is active against HCoV-229E, but not SARS-CoV-2. Still, most of the pocket residues are conserved, underscoring the relevance of this nsp15 interface pocket for drug design. The role of this protein region in forming inter-monomer interactions is evident from reports that nsp15 exists as a monomer when key interactions in this region (i.e. Arg61-Glu266 in SARS-CoV nsp15 and Tyr58-Glu263 in MERS-CoV nsp15) are eliminated by mutation. 19, 47 When nsp15 is unable to hexamerize, the EndoU catalytic site undergoes important structural changes that abolish RNA binding and enzymatic activity. 48 To conclude, the nsp15 binding mode of 5h, predicted by docking, nicely accords with the biological findings. Namely, the binding model rationalizes the requirement of the 1,2,3-triazolo function and carboxylate substituent; 5h resistance of the nsp15-K60R, -T66I and -H250A mutant viruses; and lack of activity against SARS-CoV-2.

To conclude, we present the first prototype of CoV nsp15 inhibitors, having a 1,2,3-triazolo fused betulonic acid structure. The SAR analysis, resistance data and docking model provide strong evidence that lead molecule 5h binds to an inter-monomer nsp15 interface lying adjacent to the EndoU catalytic core. This provides an excellent basis to modify the substituents or betulonic acid scaffold, and expand the activity spectrum beyond HCoV-229E. Since 5h appears to interact with the catalytic His250 residue in the EndoU domain of nsp15, the molecule plausibly interferes with the role of EndoU in regulating viral dsRNA synthesis. 24 To complement the findings in this report, 

To a solution of betulin (50.0 g, 113 mmol; purchased from Eburon Organics BVBA) in acetone (1500 mL, use ultra-sonic bath to dissolve) was added freshly prepared Jones reagent [Na2Cr2O7, Betulonic acid (100 mg, 1 equiv., 0.220 mmol), 3,4,5-trimethoxybenzylamine (56 mg, 1.3 equiv., 0.286 mmol), 4-nitrophenyl azide (36 mg, 1 equiv., 0.220 mmol), 4 Å molecular sieves (50 mg) and toluene (0.5 mL). Reaction time is overnight. The product was purified by flash column chromatography (first washed with CH2Cl2 followed by petroleum ether : 

Betulonic acid (100 mg, 1 equiv., 0.220 mmol), 3,5-dimethoxybenzylamine (48 mg, 1.3 equiv., 0.286 mmol), 4-nitrophenyl azide (36 mg, 1 equiv., 0.220 mmol), 4 Å molecular sieves (50 mg) and toluene (0.5 mL). Reaction time is overnight. The product was purified by flash column chromatography (first washed with CH2Cl2 followed by petroleum ether : 

Betulonic acid (100 mg, 1 equiv., 0.220 mmol), 4-methylbenzylamine (35 mg, 1.3 equiv., 0.286 mmol), 4-nitrophenyl azide (36 mg, 1 equiv., 0.220 mmol), 4 Å molecular sieves (50 mg) and toluene (0.5 mL). Reaction time is overnight. The product was purified by flash column chromatography (first washed with CH2Cl2 followed by petroleum ether : 

Betulonic acid (100 mg, 1 equiv., 0.220 mmol), 4-fluorobenzylamine (36 mg, 1.3 equiv., 0.286 mmol), 4-nitrophenyl azide (36 mg, 1 equiv., 0.220 mmol), 4 Å molecular sieves (50 mg) and toluene (0.5 mL). Reaction time is overnight. The product was purified by flash column chromatography (first washed with CH2Cl2 followed by petroleum ether : 

Betulonic acid (100 mg, 1 equiv., 0.220 mmol), 4-(trifluoromethyl)benzylamine (50 mg, 1.3 equiv., 0.286 mmol), 4-nitrophenyl azide (36 mg, 1 equiv., 0.220 mmol), 4 Å molecular sieves (50 mg) 23 and toluene (0.5 mL). Reaction time is overnight. The product was purified by flash column chromatography (first washed with CH2Cl2 followed by petroleum ether : 

Betulonic acid (100 mg, 1 equiv., 0.220 mmol), 4-(dimethylamino)benzylamine (43 mg, 1.3 equiv., 0.286 mmol), 4-nitrophenyl azide (36 mg, 1 equiv., 0.220 mmol), 4 Å molecular sieves (50 mg) and toluene (0.5 mL). Reaction time is overnight. The product was purified by flash column chromatography (first washed with CH2Cl2 followed by petroleum ether : 

Betulonic acid (100 mg, 1 equiv., 0.220 mmol), (S)-(−)-α-methylbenzylamine (35 mg, 1.3 equiv, 0.286 mmol), 4-nitrophenyl azide (36 mg, 1 equiv., 0.220 mmol), 4 Å molecular sieves (50 mg) and toluene (0.5 mL). Reaction time is overnight. The product was purified by flash column chromatography (first washed with CH2Cl2 followed by petroleum ether : 

Betulonic acid (100 mg, 1 equiv., 0.220 mmol), cyclohexanemethylamine (33 mg, 1.3 equiv., 0.286 mmol), 4-nitrophenyl azide (36 mg, 1 equiv., 0.220 mmol), 4 Å molecular sieves (50 mg) and toluene (0.5 mL). Reaction time is overnight. The product was purified by flash column chromatography (first washed with CH2Cl2 followed by petroleum ether : 

Betulonic acid (100 mg, 1 equiv., 0.220 mmol), piperonylamine ( 

Betulonic acid (100 mg, 1 equiv., 0.220 mmol), furfurylamine (28 mg, 1.3 equiv., 0.286 mmol), 4nitrophenyl azide (36 mg, 1 equiv., 0.220 mmol), 4 Å molecular sieves (50 mg) and toluene (0.5 mL). Reaction time is overnight. The product was purified by flash column chromatography (first washed with CH2Cl2 followed by petroleum ether : 

Betulonic acid (100 mg, 1 equiv., 0.220 mmol), tryptamine (46 mg, 1.3 equiv., 0.286 mmol), 4nitrophenyl azide (36 mg, 1 equiv., 0.220 mmol), 4 Å molecular sieves (50 mg) and toluene (0.5 mL). Reaction time is overnight. The product was purified by flash column chromatography (first 

Betulonic acid (100 mg, 1 equiv., 0.220 mmol), 5-methoxytryptamine (54 mg, 1.3 equiv., 0.286 mmol), 4-nitrophenyl azide (36 mg, 1 equiv., 0.220 mmol), 4 Å molecular sieves (50 mg) and toluene (0.5 mL). Reaction time is overnight. The product was purified by flash column chromatography (first washed with CH2Cl2 followed by petroleum ether : 

Betulonic acid (100 mg, 1 equiv., 0.220 mmol), 4-(aminomethyl) indole (42 mg, 1.3 equiv., 0.286 mmol), 4-nitrophenyl azide (36 mg, 1 equiv., 0.220 mmol), 4 Å molecular sieves (50 mg) and toluene (0.5 mL). Reaction time is overnight. The product was purified by flash column chromatography (first washed with CH2Cl2 followed by petroleum ether : 

Betulonic acid (100 mg, 1 equiv., 0.220 mmol), ethanolamine ( 

Betulonic acid (100 mg, 1 equiv., 0.220 mmol), 

Betulonic acid (100 mg, 1 equiv., 0.220 mmol), ammonium acetate (85 mg, 5 equiv., 1.100 mmol), 

Betulonic acid (100 mg, 1 equiv., 0.220 mmol), benzylamine (31 mg, 1.3 equiv., 0.286 mmol), 4nitrophenyl azide (36 mg, 1 equiv., 0.220 mmol), 4 Å molecular sieves (50 mg) and toluene (0.5 mL). Reaction time is overnight. The product was purified by flash column chromatography (first washed with CH2Cl2 followed by petroleum ether : 

Betulonic acid (100 mg, 1 equiv., 0.220 mmol), (R)-(+)-α-methylbenzylamine (35 mg, 1.3 equiv.,

Lupenone (100 mg, 1 equiv., 0.235 mmol; provided by Milan Urban), (R)-(+)-α-methylbenzylamine and cycle sequencing on the entire viral genome using a set of 39 primers (sequences available upon request). After sequence assembly with CLC Main Workbench 7.9.1 (Qiagen), the sequences of the viruses passaged in the absence and presence of 5h were aligned in order to identify the 5h resistance sites in the HCoV-229E genome.

The virus yield assay was performed in 96-well plates with semiconfluent cultures of human bronchial epithelial 16HBE cells (a gift from P. Hoet, Leuven, Belgium) or confluent HEL cells.

Serial dilutions of compound 5h were added and the cells were infected (MOI: 100) with wild-type

HCoV-229E (229E-WT), EndoU-deficient HCoV-229E (229E-H250Ansp15) 22 or the mutant viruses obtained by passaging under 5h (229E-K60Rnsp15 or 229E-T66Insp15). After 4 h incubation at 35°C, the inoculum was removed, the compound dilutions were added again and the plates were further incubated. At three days p.i., the supernatants were collected, and 2 µL of each supernatant was lysed on ice by adding 11 µL lysis mix containing lysis enhancer and resuspension buffer at a 1:10 ratio. The lysates were incubated for 10 min at 75°C and the viral RNA copy number was determined by RT-qPCR as described above for the time-of-addition assay. The data were collected in three independent experiments and expressed as the fold reduction in viral RNA compared to the virus control receiving no compound.

Starting from the published X-ray structure of hexameric nsp15 protein from HCoV-229E (PDB code: 4RS4), we first introduced a series of mutations, i.e. S10Q, S17G, A142T, M219I and S252L, to obtain the nsp15 protein sequence identical to that of the TCID50: 50% tissue culture infective dose

4 Å molecular sieves (50 mg) and toluene (0.5 mL). Reaction time is overnight. The product was purified by flash column chromatography (first washed with CH2Cl2 followed by petroleum ether : EtOAc 9:1 → 6:4 ) affording 5s (88 mg, 69% yield) as off white crystals. m.p. 327 °C. 1 H NMR (600 MHz, CDCl3) δ 7.30 -7.20 (m, 3H), 7.15 -7.10 (m, 2H), 5.73 (m, 1H)

Dihydrobetulonic acid (100 mg, 1 equiv., 0.219 mmol), (S)-(−)-α-methylbenzylamine (34 mg

(the nucleoside form of remdesivir; from Carbosynth). After five days incubation at 35°C, microscopy was performed to score virus-induced CPE. To next perform the colorimetric MTS cell viability assay, the reagent (CellTiter 96 ® AQueous MTS Reagent from Promega) was added to the wells, and 24 h later, absorbance at 490 nm was measured in a plate reader

After cell fixation with 3.7% formaldehyde in PBS for 15 min, and permeabilization with 0.2% Triton X-100 in PBS for 10 min, unspecific binding sites were blocked with 1% BSA in PBS for 30 min. Next, 1 h incubation was done with mouse monoclonal anti-dsRNA antibody

Cell nuclei were stained with DAPI (4',6-diamidino-2-phenylindole, Invitrogen) in PBS for 20

Microscopic images were acquired using the Leica TCS SP5 confocal microscope (Leica Microsystems) with a HCX PL APO 63x (NA 1.2) water immersion objective. DAPI and AlexaFluor488 were detected with excitation lines at 405 nm (blue) and 488 nm (green), and emission lines of 410-480 nm (blue)

A novel coronavirus outbreak of global health concern

Epidemiology, genetic recombination, and pathogenesis of coronaviruses

Clinical impact of human coronaviruses 229E and OC43 infection in diverse adult populations

Human coronaviruses 229E and NL63: close yet still so far

Coronaviruses: an overview of their replication and pathogenesis

SARS-CoV-2 infections in children and young people

Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation

COVID-19: drug targets and potential treatments

Coronavirus biology and replication: implications for SARS-CoV-2

COVID-19 antibodies on trial

Remdesivir for 5 or 10 days in patients with severe Covid-19

Structural basis for inhibition of the RNAdependent RNA polymerase from SARS-CoV-2 by remdesivir

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Crystal structure and mechanistic determinants of SARS coronavirus nonstructural protein 15 define an endoribonuclease family

Crystallization and preliminary X-ray crystallographic analysis of a nonstructural protein 15 mutant from human coronavirus 229E

Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2

New antiviral target revealed by the hexameric structure of mouse hepatitis virus nonstructural protein nsp15

Structural and biochemical characterization of endoribonuclease Nsp15 encoded by Middle East Respiratory Syndrome Coronavirus

Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus

Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages

Early endonuclease-mediated evasion of RNA sensing ensures efficient coronavirus replication

Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors

Physiologic RNA targets and refined sequence specificity of coronavirus EndoU

Old" protein with a new story: Coronavirus endoribonuclease is important for evading host antiviral defenses

Betulinic acid and its derivatives: a patent review

Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection

Second generation inhibitors of HIV-1 maturation

Modulation of polypeptide conformation through donor-acceptor transformation of side-chain hydrogen bonding ligands

The 1,2,3-triazole ring as a bioisostere in medicinal chemistry

3-Triazoles as amide bioisosteres: discovery of a new class of potent HIV-1 Vif antagonists

CuAAC-ensembled 1,2,3-triazole-linked isosteres as pharmacophores in drug discovery: review

A general metal-free route towards the synthesis of 1,2,3-triazoles from readily available primary amines and ketones

Chemoselectivity in the synthesis of 1,2,3-triazoles from enolizable ketones, primary alkylamines, and 4-nitrophenyl azide

Straightforward synthesis of enantiomerically pure 1,2,3-triazoles derived from amino esters

Antiproliferative effect of mitochondria-targeting allobetulin 1,2,3-triazolium salt derivatives and their mechanism of inducing apoptosis of cancer cells

Synthesis of betulinic acid from betulin extract and study of the antiviral and antiulcer activity of some related terpenoids

Study of the betulin enriched birch bark extracts effects on human carcinoma cells and ear inflammation

Toward a benign strategy for the manufacturing of betulinic acid

Effective method of purification of betulin from birch bark: the importance of its purity for scientific and medicinal use

Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the Middle East respiratory syndrome virus

Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease

RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak

Identification of TMEM106B as proviral host factor for SARS-CoV-2. bioRxiv

Structural and functional analyses of the severe acute respiratory syndrome coronavirus endoribonuclease Nsp15

Crystal structure of

A simple method of estimating fifty per cent endpoints

Synthesis and anticoronavirus activity of a series of 1-thia-4-azaspiro

Influenza virus entry via the GM3

ganglioside-mediated platelet-derived growth factor receptor beta signalling pathway

Reprogramming of the antibacterial drug vancomycin results in potent antiviral agents devoid of antibacterial activity

 1 H NMR and 13 C NMR spectra of the synthesized compounds.

*E-mail: lieve.naesens@kuleuven.be. Phone: (+32)16322098.

Joice Thomas, Arcus Biosciences, Hayward, CA 94545, United States.

The authors declare no conflict of interest.